This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.
Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.
Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.
What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
by Zacks Equity Research
Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.
Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus
by Zacks Equity Research
Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
by Arpita Dutt
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
Company News For Oct 17, 2017
by Zacks Equity Research
Companies in the news are: EXEL,TSLA,SONC,BMI
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
by Zacks Equity Research
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.
Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Exelixis (EXEL) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
by Zacks Equity Research
Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.
Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.
Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.
Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.
ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.
Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.